Список литературы

1. Дедов, И.И. Клинические рекомендации "Алгоритмы специализированной медицинской помощи больным сахарным диабетом" (9-й выпуск, дополненный)/ред. И.И. Дедов, М.В. Шестакова, А.Ю. Майоров // Сахарный диабет. - 2019. - Т. 22. N 1S1. - С. 1 - 144. DOI: 10.14341/DM221S1

2. Глобальный доклад по диабету [Global report on diabetes]. Женева: Всемирная организация здравоохранения. - 2018. - 88 с. Лицензия: CC BY-NC-SA 3.0 IGO.

3. Miller K., Fortun J.A. Diabetic macular edema: current understanding, pharmacologic treatment options and developing therapies/Asia-Pac J Ophthalmol. - 2018. - Vol. 7. - P. 28 - 35.

4. Romero-Aroca P. et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory (review article)/J Diabetes Res. - 2016. - Vol. 2016. - 17 p.

5. Haller J.A. et al. Update on the pathophisiology, molecular biology, and treatment of macular edema/Advanced studies in ophthalmology. - 2007. - Vol. 4. N 7. - P. 178 - 190.

6. Aiello L.P. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies/Ophthalmic. Res. - 1997. - Vol. 29. N 5. - P. 354 - 362.

7. Klein R. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years/Arch Ophthalmol. - 1984. - V. 102. - P. 520 - 526.

8. Klein R. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years/Arch Ophthalmol. - 1984. - V. 102. - P. 527 - 532.

9. Klein R. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XI. The incidence of macular edema/Ophthalmology. - 1989. - V. 96. - P. 1501 - 1510.

10. Здоровье глаз и сахарный диабет. Руководство для медицинских работников. IDF и фонд Фреда Холлоуза. - Брюссель, Бельгия. - 2017. - 40 с.

11. Bourne R.R., Stevens G.A., White R.A., Smith J.L., Flaxman S.R., Price H., et al. Causes of vision loss worldwide, 1990 - 2010: a systematic analysis/Lancet Glob Health. - 2013. - V. 1. - N 6. - P. 339 - 349.

12. Липатов Д.В. Эпидемиология диабетической ретинопатии в Российской Федерации по данным федерального регистра пациентов с сахарным диабетом/Д.В. Липатов, О.К. Викулова, А.В. Железнякова, М.А. Исаков, Е.Г. Бессмертная, А.А. Толкачева, Т.А. Чистяков, М.В. Шестакова, И.И. Дедов // Сахарный диабет. - 2018. - Т. 21. N 4. - С. 230 - 240.

13. Porta M., Kohner E.M. Screening for diabetic retinopathy in Europe/Diabetic Medicine. - 1991. - V. 8. - P. 197 - 198.

14. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report N 9/Ophthalmology. - 1991. - V. 98. - P. 766 - 785.

15. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study (ETDRS) report N 1/Arch Ophthalmol. - 1985. - Vol. 103. - P. 1796-806.

16. Руководство по клинической офтальмологии/ред. А.Ф. Бровкина, Ю.С. Астахов. - М.: Медицинское информационное агентство, 2014. - 955 с.

17. Офтальмология: национальное руководство/ред. С.Э. Аветисов, Е.А. Егоров, Л.К. Мошетова, В.В. Нероев, Х.П. Тахчиди. - 2ое изд - М.: ГЭОТАР-Медиа, 2018. - 904 с. - (Серия "Национальное руководство").

18. International Council of Ophthalmology. Guidelines for Diabetic Eye Care. 2017. - 40 p.

19. Нероев В.В., Астахов Ю.С., Коротких С.А., Бобыкин Е.В., Зайцева О.В., Лисочкина А.Б., Бровкина А.Ф., Будзинская М.В., Гацу М.В., Григорьева Н.Н., Измайлов А.С., Карлова Е.В., Ковалевская М.А., Нечипоренко П.А., Панова И.Е., Рябцева А.А., Симонова С.В., Тульцева С.Н., Фурсова А.Ж., Шадричев Ф.Е., Шишкин М.М., Харлампиди М.П. Протокол выполнения интравитреального введения лекарственных препаратов. Консенсус Экспертного совета по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации "Ассоциация врачей-офтальмологов" // Вестник офтальмологии. - 2020. - Т. 136. - N 6. - С. 251 - 263. https://doi.org/10.17116/oftalma2020136062251.

20. American Academy of Ophthalmology Preferred Practice Patterns Committee. Diabetic Retinopathy Preferred Practice Pattern(R). AAO (2019); http://dx.doi.org/10.1016/j.ophtha.2019.09.025 ISSN 0161-6420/19.

21. Санитарно-эпидемиологические правила и нормативы СанПиН 2.1.3.2630-10 "Санитарно-эпидемиологические требования к организациям, осуществляющим медицинскую деятельность": [постановление Главного государственного санитарного врача РФ от 18.05.2010 N 58 (ред. от 10.06.2016).: зарегистрировано в Минюсте России 09.08.2010, рег. номер 18094]. - М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора, 2010. - 255 с. ISBN 978-5-7508-0925-7.

22. Приказ Министерства здравоохранения и социального развития РФ от 29 декабря 2008 г. N 786н "О порядке формирования и утверждении государственного задания на оказание в 2009 году высокотехнологичной медицинской помощи гражданам Российской Федерации за счет ассигнований федерального бюджета" (с изменениями и дополнениями): (зарегистрировано в Минюсте РФ 30 декабря 2008 г., рег. номер 13056).

23. Управление плановой госпитализацией в многопрофильной больнице. Методические рекомендации N 2001/144: (утв. Минздравом РФ 09.11.2001).

24. Schields M.B. Glaucoma in diabetic patients/Ocular problems in diabetes mellitus // Blackwell Scientific Publ. - Boston. - 1992. - P. 307 - 319.

25. Virgili G. et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy/Cochrane Database Syst Rev. - 2015. - Vol. 7. - 57p.

26. Schmidt-Erfurth U. et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)/Ophthalmologica. - 2017. - Vol. 237. N 4. - P. 185 - 222.

27. Kai Yuan Tey et al. Optical coherence tomography angiography in diabetic retinopathy: a review of current applications/Eye and Vision. - 2019. - Vol. 6. - P. 37 - 47.

28. Johannesen S.K. et al. Optical coherence tomography angiography and microvascular changes in diabetic retinopathy: a systematic review/Acta Ophthalmol. - 2019. - Vol. 97. N 1. - P. 7 - 14.

29. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus/N. Engl. J. Med. - 1993. - V. 329. - P. 977-86.

30. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33/Lancet. - 1998. - V. 352. - P. 837 - 853.

31. Diabetes Control and Complication Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complication Trial/Diabetes. - 1995. - V. 44. - P. 968 - 983.

32. Stephenson J. et al. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study/Diabetologia. - 1994. - V. 37. - P. 278 - 285.

33. Stratton I.M. et al. UKPDS 50: risk factors for incidence and progression of diabetic retinopathy in type 2 diabetes over 6 years from diagnosis/Diabetologia. - 2001. - V. 44. - P. 156 - 163.

34. Keech A.C. et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial/Lancet. - 2007. - V. 370. - P. 1687 - 1697.

35. Keech A.C. et al. FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial/Lancet. - 2005. - V. 366. - P. 1849 - 1861.

36. ACCORD Study Group; ACCORD Study Eye Group, Effects of medical therapies on retinopathy progression in type 2 diabetes/N Enl J Med. - 2010. - Vol. 363. - P. 233 - 244.

37. Diabetic Retinopathy Study Research Group. Report N 8. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings/Ophthalmology. - 1981. - V. 88. - P. 583 - 600.

38. Diabetic Retinopathy Study Research Group. Report N 14. Indications for photocoagulation treatment of diabetic retinopathy/Int. Ophthalmol. Clin. - 1987. - V. 27. - P. 239 - 252.

39. Evans J.R., Michelessi M., Virqili G. Laser photocoagulation for proliferative diabetic retinopathy/Cochrane Database Syst Rev. - 2014. - Vol. 24. N 11. - 47 p.

40. Moutray T. et al. Different lasers and techniques for proliferative diabetic retinopathy/Cochrane Database Syst Rev. - 2018. - 104 p.

41. Gross J.G. et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial/JAMA. - 2015. - Vol. 314. - N 20. - P. 2137 - 2146.

42. Nguyen Q.D. et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE/Ophthalmology. - 2012. - Vol. 119. - P. 789 - 801.

43. Do D.V. et al. One-year outcomes of the DA Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema/Ophthalmology. - 2012. - Vol. 119. - P. 1658 - 1665.

44. Brown D.M. et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema/American Journal of Ophthalmology. - 2022. - Vol. 238. - P. 157 - 172. doi: https://doi.org/10.1016/j.ajo.2022.01.004

45. Boyer D.S. et al. Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema/Ophthalmology. - 2014. - Vol. 121. - P. 1904 - 1914.

46. Elman M.J. et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results/Ophthalmology. - 2015. - Vol. 122. N 2. - P. 375 - 381.

47. Wells J.A. et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema/N Engl J Med. - 2015. - Vol. 372. - P. 1193 - 1203.

48. Wells J.A. et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial/Ophthalmology. - 2016. - Vol. 123. N 6. - P. 1351 - 1359.

49. Papadopoulos N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab/Angiogenesis. - 2012. - Vol. 15. - P. 171 - 185.

50. WHO. Prevention of blindness from diabetes mellitus/Report of a WHO consultation in Geneva 9 - 11 November 2005. - Switzerland. - WHO press. - 2005. - p. 39.

51. Massin P. et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study/Diabetes Care. - 2010. - V. 33. N 11. - P. 2399 - 2405.

52. Mitchell P. et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema/Ophthalmology. - 2011. - V. 118, N. 4. - P. 615 - 625.

53. Do D.V. et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema/Ophthalmology. - 2011. - Vol. 118. - P. 1819 - 1826.

54. Brown D.M. et al. Intravitreal aflibercept for diabetic macular edema. 100 week results from the VISTA and VIVID studies/Ophthalmology. - 2015. - Vol. 122. - P. 1 - 9.

55. Elman M.J. et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema/Ophthalmology. - 2010. - Vol. 117. N 6. - P. 1064 - 1077.

56. Callanan D.G. et al. Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema/Ophthalmology. - 2013. - Vol. 120. N 9. - P. 843 - 851.

57. Haller J.A. et al. Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema/Arch. Ophthalmol. - 2010. - Vol. 128. N 3. - P. 289 - 296.

58. Giovannini A. et al. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach/European Journal of Ophthalmology. - 2019. - Vol. 29. N 1. - P. 82 - 91.

59. Forooghian F. et al. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept./Canadian Journal of Ophthalmology - 2017. - Vol. 52. N 6. - P. 616 - 619.

60. Бойко Э.В., Даниличев В.Ф., Сажин Т.Г. и др. Методы клинического применения рекомбинантной проурокиназы в офтальмологической практике // РМЖ. Клиническая офтальмология. 2017. N 2. С. 118 - 129.

61. Flynn H.W. et al. Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The early treatment diabetic retinopathy study research group/Ophthalmology. - 1992. - Vol. 99. - P. 1351 - 1357.

62. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial - Diabetic retinopathy vitrectomy study report 4. The diabetic retinopathy vitrectomy study research group/Ophthalmology. - 1988. Vol. 95. - P. 1321 - 1334.

63. Херш П.С., Загельбаум Б.М., Кремерс С.Л. Офтальмохирургия. Пер. с англ./М.: Мед. лит., Витебск - 2016. - 400 с.

64. Tsui M.-C. et al. Silicone oil removal after extended tamponade in proliferative diabetic retinopathy - long range of follow-up/Eye. - 2020. - Vol. 34. - P. 2307 - 2314

65. Laurenzi A., Bolla A.M., Panigoni G., Doria V., Uccellatore A., Peretti E., et al. Effects of Carbohydrate Counting on Glucose Control and Quality of Life Over 24 Weeks in Adult Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion: A randomized, prospective clinical trial (GIOCAR). Diabetes Care. 2011; 34(4): 823 - 827. doi: 10.2337/dc10-1490.

66. Samann A., Muhlhauser I., Bender R., Kloos C., Muller U.A. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia. 2005; 48(10): 1965 - 1970. doi: 10.1007/s00125-005-1905-1.

67. Bell K.J., Barclay A.W., Petocz P., Colagiuri S., Brand-Miller J.C. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2014; 2(2): 133 - 140. doi: 10.1016/S2213-8587(13)70144-X.

68. Elliott J., Lawton J., Rankin D., Emery C., Campbell M., Dixon S., et al. The 5 x 1 DAFNE study protocol: a cluster randomised trial comparing a standard 5 day DAFNE course delivered over 1 week against DAFNE training delivered over 1 day a week for 5 consecutive weeks. BMC Endocr Disord. 2012; 12(1): 28. doi: 10.1186/1472-6823-12-28.

69. Haas L., Maryniuk M., Beck J., Cox C.E., Duker P., Edwards L., et al. National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2013; 36 (Supplement_1): S100 - S108. doi: 10.2337/dc13-S100.

70. Evert A.B., Boucher J.L., Cypress M., Dunbar S.A., Franz M.J., Mayer-Davis E.J., et al. Nutrition Therapy Recommendations for the Management of Adults With Diabetes. Diabetes Care. 2014; 37 (Supplement_1): S120 - S143. doi: 10.2337/dc14-S120.

71. Davies M.J., D'Alessio D.A., Fradkin J., Kernan W.N., Mathieu C., Mingrone G., et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669 - 2701. doi: 10.2337/dci18-0033.

72. Diabetes Control and Complications Trial Research Group, Nathan D.M., Genuth S., Lachin J., Cleary P., Crofford O., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977 - 986. doi: 10.1056/NEJM199309303291401.

73. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin J.M., Genuth S., Cleary P., Davis M.D., Nathan D.M. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6): 381 - 389. doi: 10.1056/NEJM200002103420603.

74. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019; 42 (Supplement 1): S61 - S70. doi: 10.2337/dc19-S006.

75. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 854 - 865.

76. UK Prospective Diabetes Study (UKPDS) Group. Intensiv blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837 - 853.

77. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545 - 2559. doi: 10.1056/NEJMoa0802743.

78. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009; 360(2): 129 - 139. doi: 10.1056/NEJMoa0808431.

79. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560 - 2572. doi: 10.1056/NEJMoa0802987.

80. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A.M., et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology. Diabetes Care. 2009; 32(1): 187 - 192. doi: 10.2337/dc08-9026.

81. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., et al. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет [Internet]. 2011; 14(4): 6 - 17. doi: 10.14341/2072-0351-5810.

82. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577 - 1596. doi: 10.1007/s00125-012-2534-0.

83. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016; 39(7): 1089 - 1100. doi: 10.2337/dc16-0024.

84. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J. Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care. 2008; 31(8): 1473 - 1478. doi: 10.2337/dc08-0545.

85. Fisher M. Statins for people with type 1 diabetes: when should treatment start? Pract Diabetes. 2016; 33(1): 10 - 11. doi: 10.1002/pdi.1990.

86. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607): 117 - 125. doi: 10.1016/S0140-6736(08)60104-X.

87. Rabar S., Harker M., O'Flynn N., Wierzbicki A.S. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014; 349(12): g4356. doi: 10.1136/bmj.g4356.

88. Livingstone S.J., Looker H.C., Hothersall E.J., Wild S.H., Lindsay R.S., Chalmers J., et al. Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. Lehman R., editor. PLoS Med. 2012; 9(10): e1001321. doi: 10.1371/journal.pmed.1001321.

89. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326): 7 - 22. doi: 10.1016/S0140-6736(02)09327-3.

90. Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., DelgadoV, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; doi: 10.1093/eurheartj/ehz486.

91. Hansen T.W., Kikuya M., Thijs L., Li Y., Boggia J., Bjorklund-Bodegard K., et al. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. J Clin Hypertens (Greenwich). 2008; 10(5): 377 - 381.

92. Arguedas J.A., Leiva V., Wright J.M. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane database Syst Rev. 2013; (10): CD008277. doi: 10.1002/14651858 .CD008277.pub2.

93. Thomopoulos C., Parati G., Zanchetti A. Effects of bloodpressure-lowering treatment on outcome incidence in hypertension. J Hypertens. 2017; 35(5): 922 - 944. doi: 10.1097/HJH. 0000000000001276.

94. Bulugahapitiya U., Siyambalapitiya S., Sithole J., Idris I. Is diabetes a coronary risk equivalent? Systematic review and metaanalysis. Diabet Med. 2009; 26(2): 142 - 148. doi: 10.1111/j.1464-5491.2008.02640.x.

95. Brunstrom M., Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016; 352: i717. doi: 10.1136/bmj.i717.

96. Rawshani A., Rawshani A., Franzen S., Eliasson B., Svensson A-M, Miftaraj M., et al. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2017; 135(16): 1522 - 1531. doi: 10.1161/CIRCULATIONAHA.116.025961.

97. Xie X., Atkins E., Lv J., Bennett A., Neal B., Ninomiya T., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387(10017): 435 - 443. doi: 10.1016/S0140-6736(15) 00805-3.

98. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A.W., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004; 364(9435): 685 - 696. doi: 10.1016/S0140-6736(04) 16895-5.

99. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267 - 1278. doi: 10.1016/S0140-6736(05)67394-1.

100. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999 - 3058. doi: 10.1093/eurheartj/ehw272.

101. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., et al. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019; 73(24): e285 - e350. doi: 10.1016/j.jacc.2018.11.003.

102. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J., O'Connell R., Voysey M., Emberson J., Blackwell L., et al. Efficacy and safety of LDL-lowering therapy among men and women: metaanalysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397 - 1405. doi: 10.1016/S0140-6736(14) 61368-4.

103. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670 - 1681. doi: 10.1016/S0140-6736(10)61350-5.

104. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547 - 1559. doi: 10.1056/NEJMoa0801317.

105. Grenier J., Goodman S.G., Leiter L.A., Langer A., Teoh H., Bhatt D.L., et al. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Can J Diabetes. 2018; 42(2): 130 - 137. doi: 10.1016/j.jcjd. 2017. 01.005.

106. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P., Goff D.C., Grimm R.H., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1575 - 1585. doi: 10.1056/NEJMoa1001286.

107. Diabetic Retinopathy: A Position Statement by American Diabetes Association/Diabetes Care. - 2017. - Vol. 40. - P. 412 - 418.

108. Hooper P. et al. Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee. Canadian Ophthalmological Society evidence based clinical practice guidelines for the management of diabetic retinopathy/Can J Ophthalmol. - 2012. - Vol. 47. - P. 91 - 96.

109. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Microvascular and macrovascular complications in children and adolescents/Pediatric Diabetes. - 2014. - Vol. 15. Suppl. 20. - P. 257 - 269.